TY - JOUR
T1 - Inflammatory cytokine and humoral responses to plasmodium falciparum glycosylphosphatidylinositols correlates with malaria immunity and pathogenesis
AU - Mbengue, Babacar
AU - Niang, Birahim
AU - Sylla Niang, Maguette
AU - Varela, Marie Louise
AU - Fall, Becaye
AU - Fall, Mouhamadou Mansour
AU - Ndiaye Diallo, Rokhaya
AU - Diatta, Bacary
AU - Gowda, D. Channe
AU - Dieye, Alioune
AU - Perraut, Ronald
N1 - Publisher Copyright:
© 2015 The Authors.
PY - 2016/3
Y1 - 2016/3
N2 - Pro-inflammatory cytokines induced by glycosylphosphatidylinositols (GPIs) of Plasmodium falciparum contribute to malaria pathogenesis and hence, the naturally acquired anti-GPI antibody thought to provide protection against severe malaria (SM) by neutralizing the stimulatory activity of GPIs. In previous studies, the anti-GPI antibody levels increased with age in parallel with the development of acquired immunity, and high levels of anti-GPI antibodies were associated with mild malaria (MM) cases. In the present study, the relationship between the levels of pro-inflammatory cytokines and anti-GPI IgG antibody responses, parasitemia, and the clinical outcomes were evaluated in SM and mild malaria (MM) patients. Sera from a total of 110 SM and 72 MM cases after excluding of ineligible patients were analyzed for the levels of anti-GPI antibodies, IgG subclasses, and cytokine responses by ELISA. While the total anti-GPI antibody levels were similar in overall SM and MM groups, they were significantly higher in surviving SM patients than in fatal SM cases. In the case of cytokines, the TNF-α and IL-6 levels were significantly higher in SM compared to MM, whereas the IL-10 levels were similar in both groups. The data presented here demonstrate that high levels of the circulatory proinflammatory, TNF-α, and IL-6, are indicators of malaria severity, whereas antiinflammatory cytokine IL-10 level does not differentiate SM and MM cases. Further, among SM patients, relatively low levels of anti-GPI antibodies are indicators of fatal outcomes compared to survivors, suggesting that anti-GPI antibodies provide some level of protection against SM fatality.
AB - Pro-inflammatory cytokines induced by glycosylphosphatidylinositols (GPIs) of Plasmodium falciparum contribute to malaria pathogenesis and hence, the naturally acquired anti-GPI antibody thought to provide protection against severe malaria (SM) by neutralizing the stimulatory activity of GPIs. In previous studies, the anti-GPI antibody levels increased with age in parallel with the development of acquired immunity, and high levels of anti-GPI antibodies were associated with mild malaria (MM) cases. In the present study, the relationship between the levels of pro-inflammatory cytokines and anti-GPI IgG antibody responses, parasitemia, and the clinical outcomes were evaluated in SM and mild malaria (MM) patients. Sera from a total of 110 SM and 72 MM cases after excluding of ineligible patients were analyzed for the levels of anti-GPI antibodies, IgG subclasses, and cytokine responses by ELISA. While the total anti-GPI antibody levels were similar in overall SM and MM groups, they were significantly higher in surviving SM patients than in fatal SM cases. In the case of cytokines, the TNF-α and IL-6 levels were significantly higher in SM compared to MM, whereas the IL-10 levels were similar in both groups. The data presented here demonstrate that high levels of the circulatory proinflammatory, TNF-α, and IL-6, are indicators of malaria severity, whereas antiinflammatory cytokine IL-10 level does not differentiate SM and MM cases. Further, among SM patients, relatively low levels of anti-GPI antibodies are indicators of fatal outcomes compared to survivors, suggesting that anti-GPI antibodies provide some level of protection against SM fatality.
UR - http://www.scopus.com/inward/record.url?scp=84985030014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84985030014&partnerID=8YFLogxK
U2 - 10.1002/iid3.89
DO - 10.1002/iid3.89
M3 - Article
AN - SCOPUS:84985030014
SN - 2050-4527
VL - 4
SP - 24
EP - 34
JO - Immunity, inflammation and disease
JF - Immunity, inflammation and disease
IS - 1
ER -